Half-Life of Labetalol
The elimination half-life of labetalol following oral administration is approximately 6 to 8 hours in healthy adults, and this half-life remains unchanged in patients with hepatic impairment, though bioavailability increases significantly due to reduced first-pass metabolism. 1
Pharmacokinetics in Healthy Adults
The FDA-approved labeling clearly establishes that labetalol has a plasma half-life of about 6 to 8 hours following oral administration 1. This is consistent across multiple research studies, which report elimination half-lives ranging from 3 to 4.9 hours after intravenous administration 2, 3, 4 and approximately 6 hours after oral dosing 5, 3.
Key pharmacokinetic parameters in healthy individuals include:
- Peak plasma levels occur 1 to 2 hours after oral administration 1
- Steady-state plasma levels are reached by approximately the third day of dosing 1
- Absolute bioavailability is only 25% due to extensive first-pass hepatic metabolism 1
- The drug is approximately 50% protein bound 1
Critical Alteration in Hepatic Impairment
In patients with decreased hepatic function, the elimination half-life of labetalol is NOT altered; however, the relative bioavailability is markedly increased due to decreased first-pass metabolism 1. This is a crucial clinical distinction that directly impacts dosing.
Research demonstrates that:
- Bioavailability increases from approximately 25% in healthy subjects to significantly higher levels in patients with chronic liver disease 6
- Plasma concentrations after oral administration are considerably higher in patients with liver disease compared to healthy subjects, while concentrations after intravenous injection remain similar 6
- Bioavailability correlates negatively with serum albumin concentration in patients with liver disease 6
- The increased bioavailability results in exaggerated hemodynamic responses (greater falls in heart rate and blood pressure) 6
Clinical Implications
Oral dosage requirements of labetalol must be reduced in the presence of liver disease 6. While the FDA label states that the elimination half-life is not altered in hepatic impairment 1, the increased bioavailability means patients are exposed to higher drug concentrations from the same oral dose, necessitating dose reduction to avoid excessive hypotension and other adverse effects.
Important Caveats:
- Elderly patients show reduced elimination of labetalol and generally require lower maintenance doses than younger patients 1
- Neither hemodialysis nor peritoneal dialysis removes significant amounts of labetalol (<1%) 1
- The drug undergoes mainly hepatic metabolism through conjugation to glucuronide metabolites, with 55-60% appearing in urine within 24 hours 1